nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.07.2012 | Review

Molecular insights on basal-like breast cancer

verfasst von: Mev Dominguez Valentin, Sabrina Daniela da Silva, Maud Privat, Moulay Alaoui-Jamali, Yves-Jean Bignon

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Molecular classification of breast cancer (BC) identified diverse subgroups that encompass distinct biological behavior and clinical implications, in particular in relation to prognosis, spread, and incidence of recurrence. Basal-like breast cancers (BLBC) compose up to 15% of BC and are characterized by lack of estrogen receptor (ER), progesterone receptor (PR), and HER-2 amplification with expression of basal cytokeratins 5/6, 14, 17, epidermal growth factor receptor (EGFR), and/or c-KIT. There is an overlap in definition between triple-negative BC and BLBC due to the triple-negative profile of BLBC. Also, most BRCA1-associated BCs are BLBC, triple negative, and express basal cytokeratins (5/6, 14, 17) and EGFR. There is a link between sporadic BLBC (occurring in women without germline BRCA1 mutations) with dysfunction of the BRCA1 pathway. Despite the molecular and clinical similarities, these subtypes respond differently to neoadjuvant therapy. BLBCs are associated with an aggressive phenotype, high histological grade, poor clinical behavior, and high rates of recurrences and/or metastasis. Their molecular features render these tumors especially refractory to anti-hormonal-based therapies and the overall prognosis of this subset remains poor. In this article, the molecular profile, genomic, and epigenetic characteristics as well as BRCA1 pathway dysfunction, clinicopathological behavior, and therapeutic options in BLBC are presented, with emphasis on the discordant findings in current literature.

Haupt B, Ro JY, Schwartz MR (2010) Basal-like breast carcinoma: a phenotypically distinct entity. Arch Pathol Lab Med 134:130–133PubMed

Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32PubMedCrossRef

Presson AP, Yoon NK, Bagryanova L et al (2011) Protein expression based multimarker analysis of breast cancer samples. BMC Cancer. doi:10.1186/1471-2407-11-230

Weigelt B, Reis-Filho JS (2010) Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res. doi:10.1186/BCR2734

Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumour. Nature 406:747–752PubMedCrossRef

Yehiely F, Moyano JV, Evans JR et al (2006) Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12(11):537–544PubMedCrossRef

Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef

Niemeier LA, Dabbs DJ, Beriwal S et al (2010) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23:205–212PubMedCrossRef

Irvin WJ Jr, Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44:2799–2805PubMedCrossRef

10.

Rakha EA, Elsheikh SE, Aleskandarany MA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2302–2310PubMedCrossRef

11.

Schneider BP, Winer EP, Foulkes WD et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14:8010–8018 ReviewPubMedCrossRef

12.

Gastaldi S, Comoglio PM, Trusolino L (2010) The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res. doi:10.1186/BCR2617

13.

Herschkowitz JI, Simin K, Weigman VJ et al (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. doi: 10.1186/gb-2007-8-5-r76

14.

Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69:4116–4124PubMedCrossRef

15.

Prat A, Parker JS, Karginova O et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. doi:10.1186/BCR2635

16.

Herschkowitz JI, Zhao W, Zhang M et al (2011) Breast cancer special feature: comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci USA. doi:10.1073/pnas.1018862108

17.

Farmer P, Bonnefoi H, Becette V et al (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24:4660–4671PubMedCrossRef

18.

Lopez-Garcia MA, Geyer FC, Lacroix-Triki M et al (2010) Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 57:171–192PubMedCrossRef

19.

Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374PubMedCrossRef

20.

Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423PubMedCrossRef

21.

Böcker W, Bier B, Freytag G et al (1992) An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part I: normal breast and benign proliferative lesions. Virchows Arch A Pathol Anat Histopathol 421:315–322PubMedCrossRef

22.

Korsching E, Packeisen J, Agelopoulos K et al (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Investig 82:1525–1533PubMed

23.

Choo JR, Nielsen TO (2010) Biomarkers for basal-like breast cancer. Cancers 2:1040–1065CrossRef

24.

Khramtsov AI, Khramtsova GF, Tretiakova M et al (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176:2911–2920PubMedCrossRef

25.

Turashvili G, Bouchal J, Burkadze G et al (2006) Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 73:213–223PubMedCrossRef

26.

Rubovszky G, Udvarhelyi N, Horváth Z et al (2010) Triple-negative breast carcinoma—review of current literature. Magy Onkol 54:325–335 ReviewPubMedCrossRef

27.

Honeth G, Bendahl PO, Ringnér M et al (2008) The CD44+/CD24− phenotype is enriched in basal-like breast tumors. Breast Cancer Res. doi:10.1186/BCR2108

28.

Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568–2581 ReviewPubMedCrossRef

29.

Kwei KA, Kung Y, Salari K et al (2010) Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol 4:255–256PubMedCrossRef

30.

Bergamaschi A, Kim YH, Wang P et al (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45:1033–1040PubMedCrossRef

31.

Toft DJ, Cryns VL (2011) Minireview: basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol 25:199–211 ReviewPubMedCrossRef

32.

Letessier A, Sircoulomb F, Ginestier C et al (2006) Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer. doi:10.1186/1471-2407-6-245

33.

Adélaïde J, Finetti P, Bekhouche I et al (2007) Integrated profiling of basal and luminal breast cancers. Cancer Res 67:11565–11575PubMedCrossRef

34.

Wang ZC, Lin M, Wei LJ et al (2004) Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 64:64–71PubMedCrossRef

35.

Liu F, Chen X, Allali-Hassan A et al (2009) Discovery of a 2, 4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem 52:7950–7953PubMedCrossRef

36.

Roll JD, Rivenbark AG, Jones WD et al (2008) DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer. doi:10.1186/1476-4598-7-15

37.

Parrella P, Poeta ML, Gallo AP et al (2004) Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 10:5349–5354PubMedCrossRef

38.

Li S, Rong M, Iacopetta B (2006) DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 237:272–280PubMedCrossRef

39.

Holm K, Hegardt C, Staaf J et al (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. doi:10.1186/BCR2590

40.

Bae YK, Brown A, Garrett E et al (2004) Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res 10:5998–6005PubMedCrossRef

41.

Dumont N, Wilson MB, Crawford YG et al (2008) Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci USA 105:14867–14872PubMedCrossRef

42.

Elsheikh SE, Green AR, Rakha EA et al (2009) Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69:3802–3809PubMedCrossRef

43.

Van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRef

44.

Waddell N, Arnold J, Cocciardi S et al (2010) Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat 123:661–677PubMedCrossRef

45.

Hedenfalk I, Ringner M, Ben-Dor A et al (2003) Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 100:2532–2537PubMedCrossRef

46.

Sørlie T (2004) Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 40:2667–2675 ReviewPubMedCrossRef

47.

Rakha EA, Reis-Filho JS, Ellis IO (2008) Impact of basal-like breast carcinoma determination for a more specific therapy. Pathobiology 75:95–103PubMedCrossRef

48.

Gorski JJ, Kennedy RD, Hosey AM et al (2009) The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clin Cancer Res 15:1514–1518PubMedCrossRef

49.

Ray PS, Wang J, Qu Y et al (2010) FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res 70:3870–3876PubMedCrossRef

50.

Yamamoto Y, Iwase H (2010) Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 15(4):341–351PubMedCrossRef

51.

Kobayashi S (2008) Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer 15:153–158PubMedCrossRef

52.

Millikan RC, Newman B, Tse CK, Moorman PG et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123–139PubMedCrossRef

53.

Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123–134PubMedCrossRef

54.

Ismail-Khan R, Bui MM (2010) A review of triple-negative breast cancer. Cancer Control 17:173–176PubMed

55.

Dong Y, Li A, Wang J et al (2010) Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res 70:5465–5474PubMedCrossRef

56.

Rodríguez-Pinilla SM, Sarrió D, Honrado E et al (2007) Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 60:1006–1012PubMedCrossRef

57.

Rodríguez-Pinilla SM, Sarrió D, Honrado E et al (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12:1533–1539PubMedCrossRef

58.

Li H, Cherukuri P, Li N et al (2007) Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 67:501–510PubMedCrossRef

59.

Parry S, Savage K, Marchiò C et al (2008) Nestin is expressed in basal-like and triple negative breast cancers. J Clin Pathol 61:1045–1050PubMedCrossRef

60.

Charafe-Jauffret E, Monville F, Bertucci F et al (2007) Moesin expression is a marker of basal breast carcinomas. Int J Cancer 121:1779–1785PubMedCrossRef

61.

Elsheikh SE, Green AR, Rakha EA et al (2008) Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 99:327–334PubMedCrossRef

62.

Pinilla SM, Honrado E, Hardisson D et al (2006) Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 99:85–90PubMedCrossRef

63.

Savage K, Lambros MB, Robertson D et al (2007) Caveolin 1 is overexpressed and basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, amplified in a subset of immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 13:90–101PubMedCrossRef

64.

Savage K, Leung S, Todd SK et al (2008) Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat 110:245–256PubMedCrossRef

65.

Lu S, Simin K, Khan A et al (2008) Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res 14:1050–1058PubMedCrossRef

66.

Reis-Filho JS, Steele D, Di Palma S et al (2006) Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol 19:307–319PubMedCrossRef

67.

Hasegawa M, Moritani S, Murakumo Y et al (2008) CD109 expression in basal-like breast carcinoma. Pathol Int 58:288–294PubMedCrossRef

68.

Matos I, Dufloth R, Alvarenga M et al (2005) p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447:688–694PubMedCrossRef

69.

Paredes J, Lopes N, Milanezi F et al (2007) P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 450:73–80PubMedCrossRef

70.

Zabouo G, Imbert AM, Jacquemier J et al (2009) CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res 11:R1PubMedCrossRef

71.

Klingbeil P, Natrajan R, Everitt G et al (2010) CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res Treat 120:95–109PubMedCrossRef

72.

Viale G, Rotmensz N, Maisonneuve P et al (2009) Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116:317–328PubMedCrossRef

73.

Mani SA, Yang J, Brooks M et al (2007) Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 104:10069–10074PubMedCrossRef

74.

Umemura S, Shirane M, Takekoshi S et al (2009) Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. Br J Cancer 100:764–771PubMedCrossRef

75.

Ribeiro-Silva A, Ramalho LN, Garcia SB et al (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47:458–466PubMedCrossRef

76.

Rakha EA, Putti TC, Abd El-Rehim DM et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208:495–506PubMedCrossRef

77.

Herschkowitz JI, He X, Fan C et al (2008) The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 10(5):R75PubMedCrossRef

78.

Kuroda H, Ishida F, Nakai M et al (2008) Basal cytokeratin expression in relation to biological factors in breast cancer. Hum Pathol 39:1744–1750PubMedCrossRef

79.

Walter O, Prasad M, Lu S et al (2009) IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol 40:1528–1533PubMedCrossRef

80.

Skaland I, Janssen EA, Gudlaugsson E et al (2009) The prognostic value of the proliferation marker phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer. Cell Oncol 31:261–271PubMed

81.

Zhang H, Rakha EA, Ball GR et al (2010) The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res Treat 121:41–51PubMedCrossRef

82.

Tang XY, Umemura S, Tsukamoto H et al (2010) Overexpression of fatty acid binding protein-7 correlates with basal-like subtype of breast cancer. Pathol Res Pract 206:98–101PubMedCrossRef

83.

Moyano JV, Evans JR, Chen F et al (2006) AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116:261–270PubMedCrossRef

84.

Sitterding SM, Wiseman WR, Schiller CL et al (2008) AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol 12:33–40PubMedCrossRef

Titel: Molecular insights on basal-like breast cancer
verfasst von: Mev Dominguez Valentin
Sabrina Daniela da Silva
Maud Privat
Moulay Alaoui-Jamali
Yves-Jean Bignon
Publikationsdatum: 01.07.2012
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1934-z

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Molecular insights on basal-like breast cancer

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

An abnormal screening mammogram causes more anxiety than a palpable lump in benign breast disease

Erratum to: Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents

Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study

Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer

Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie